If your blood work at an annual visit shows that your total cholesterol falls within the “normal” range, you might assume your heart is healthy. Unfortunately, while cholesterol is an important marker of cardiovascular risk, it doesn’t capture the whole picture. Many people are surprised to learn that normal cholesterol and heart disease can exist at the same time.
LDL cholesterol (LDL-C), HDL cholesterol, triglycerides, and total cholesterol provide important information about cardiovascular risk. But those numbers aren’t a definitive assessment of what’s happening inside your arteries.
Research helps illustrate why. In a large 2009 analysis of patients hospitalized with coronary artery disease, almost half had LDL-C levels below 100 mg/dL at admission. [1] Another study, known as the PESA study, found subclinical atherosclerosis in nearly half of middle-aged adults without conventional cardiovascular risk factors. Even among those with an optimal risk profile, approximately one-third had detectable atherosclerosis. [2]
This is why we look beyond LDL-C alone when assessing heart health at Biograph. Advanced biomarkers such as apolipoprotein B (ApoB), lipoprotein(a), or Lp(a), and high-sensitivity C-reactive protein (hs-CRP) can provide additional context. And when clinically appropriate, imaging can help determine whether plaque is already accumulating in your coronary arteries.
What can a standard cholesterol panel miss?
A standard lipid panel generally measures total cholesterol, HDL cholesterol, and triglycerides and estimates LDL-C, which is foundational to cardiovascular prevention.
But LDL-C measures the amount of cholesterol being carried inside LDL particles. It doesn’t directly tell clinicians how many atherogenic, or plaque-forming, particles are circulating through your bloodstream.
This is where an advanced lipid panel can provide more clinical context and help catch disease well before it begins more efficiently.
ApoB vs. LDL: Cholesterol cargo vs. particle number
Picture ApoB and LDL-C as cars on a highway. LDL-C tells us how much cholesterol is being transported, whereas ApoB gives us a better approximation of how many atherogenic particles are carrying that cholesterol.
Each major atherogenic particle, including LDL, very-low-density lipoprotein (VLDL), and Lp(a), carries one ApoB molecule. Measuring ApoB therefore provides a more direct estimate of the number of particles capable of entering your arterial wall and contributing to atherosclerotic plaque.
While LDL-C and ApoB generally move in the same direction, they don’t always align. For instance, someone can have an LDL-C that appears to be within a goal range while their ApoB remains elevated. This discrepancy is known as discordance. When the two measurements are discordant, ApoB can provide additional information about atherogenic particle burden and cardiovascular risk. [3] [4]
The 2026 ACC/AHA dyslipidemia guideline recognizes ApoB as a useful additional measurement in certain adults, particularly when LDL-C may not fully reflect residual risk. [3]
Lp(a): A cardiovascular risk factor you may inherit
Lipoprotein(a), or Lp(a), is another atherogenic particle that can reveal cardiovascular risk your standard lipid panel may not capture. Unlike many other cardiovascular risk factors, your Lp(a) level is largely determined by your genetics.
Structurally, Lp(a) resembles an LDL particle but has an additional protein called apolipoprotein(a) attached to it. Elevated Lp(a) is independently associated with atherosclerotic cardiovascular disease, and because levels are largely genetically determined, they can remain high despite a healthy lifestyle. While diet and physical activity remain critical for your overall heart health, lifestyle changes typically have a small effect on Lp(a) levels. The only way to know your level is to measure it directly.
Current ACC/AHA guidance recommends that all adults have Lp(a) measured at least once to help assess cardiovascular risk. [3]
Having elevated Lp(a) doesn’t mean you’re destined to develop heart disease, though it can be concerning to have a high level even when your LDL-C and other cholesterol measurements appear otherwise normal.
Still, knowing it’s elevated can help your care team better understand your lifetime risk and determine how aggressively to manage the factors you can modify, including your LDL-C, blood pressure, smoking, and metabolic health.
Where hs-CRP fits in
Cholesterol and atherogenic particles aren’t the only clues clinicians can gather from your blood. Your inflammation levels can also provide additional context about your cardiovascular risk.
High-sensitivity C-reactive protein, or hs-CRP, measures very low levels of C-reactive protein, a protein that increases in response to inflammation. Persistently elevated hs-CRP is recognized as a cardiovascular risk-enhancing factor and may help identify risk that cholesterol measurements alone don’t capture. [3]
But hs-CRP isn’t specific to your heart. Levels can rise because of an infection, injury, or other sources of transient inflammation, so a single elevated result doesn’t necessarily mean you are at increased risk of cardiovascular disease.
This is why hs-CRP is most useful when interpreted alongside other information, including your lipid profile, ApoB, Lp(a), blood pressure, metabolic health, family history, and, when appropriate, cardiac imaging.
Can you have arterial plaque with normal cholesterol?
Yes. Blood biomarkers help estimate cardiovascular risk, but they don’t directly show whether or not plaque has already formed inside your arteries.
The PESA study is a good example. Remember, researchers studied middle-aged adults without conventional cardiovascular risk factors and found subclinical atherosclerosis in nearly half. Even among a subgroup with optimal risk factors, approximately one in three had evidence of atherosclerosis. [2]
This doesn’t mean everyone with normal cholesterol needs cardiac imaging, but it does reinforce this point: blood work measures risk factors, whereas imaging can identify disease that’s already present. Two forms of CT imaging can provide different information about coronary plaque, which include coronary artery calcium and CT coronary angiography scans.
Coronary artery calcium scoring
A coronary artery calcium (CAC) scan is a noninvasive CT scan that measures calcified plaque in your coronary arteries and generates a calcium score. This can indicate that atherosclerosis is already present and can help physicians better assess your cardiovascular risk and help inform certain interventions needed to improve your heart health.
But CAC has a big limitation: It detects calcified plaque, not non-calcified, or “soft,” plaque that may develop earlier on in the disease process. This means a calcium score of zero doesn’t necessarily mean your coronary arteries are completely free of plaque.
CT coronary angiography
CT coronary angiography (CTCA) provides a more detailed look at your coronary arteries. Using intravenous contrast and CT imaging, CTCA can identify calcified, non-calcified, and mixed plaque, as well as areas where the arteries have narrowed.
Among Biograph members with otherwise optimal lipid levels, approximately two-thirds have shown hidden cardiovascular findings on advanced imaging, including coronary plaque or evidence of vascular injury. And among members age 40 and older who undergo CTCA, approximately 41% have received a recommendation to modify their treatment plan based on the findings.
Now that’s not to say everyone with normal cholesterol needs a CTCA to potentially rule out underlying signs of disease. Whether cardiac imaging is appropriate depends on factors such as your age, symptoms, family history, cardiovascular risk factors, previous testing, and whether the results are likely to change your course of care.
Beyond structural plaque: AI-powered coronary inflammation mapping
While advanced blood biomarkers and CT scans offer crucial context, recent research shows that circulating blood biomarkers and standard scans can still leave significant blind spots when it comes to active vessel disease.
In an exploratory U.S. clinical study conducted by Biograph, researchers evaluated coronary perivascular inflammation in asymptomatic, low-risk adults using AI-enabled CT technology from Caristo Diagnostics (CaRi-Heart®). The findings revealed that active coronary inflammation is common in this cohort – occurring in 42.9% of asymptomatic study participants – and often exists without any visible plaque buildup or arterial blockages. [6]
Crucially, the study demonstrated that routine bloodwork and clinical risk calculators (including ApoB, hs-CRP, non-HDL-C, and the AHA PREVENT-ASCVD tool) showed no correlation with the presence of coronary inflammation. Nearly half (47%) of participants with zero detectable coronary plaque on CCTA still exhibited elevated perivascular inflammation. [6]
This reveals a critical insight for preventive cardiology: arterial inflammation often represents an upstream phase of disease that occurs in the vessel wall long before plaque accumulates or systemic blood markers spike. By directly analyzing the biology of the tissue surrounding the coronary arteries, advanced AI imaging can uncover cardiovascular risk years before structural damage takes hold.
A hypothetical example: When LDL-C doesn't tell the whole story
Consider a 48-year-old executive who runs marathons, eats well, and has an LDL-C of 92 mg/dL. Based on his standard lipid panel alone, he may feel as though he has enough data to suggest he’s in good cardiovascular health.
But suppose advanced testing reveals he has elevated ApoB and Lp(a). Based on his complete clinical picture, his physician may recommend additional evaluation. If CTCA then identifies non-calcified coronary plaque, we’ve learned something his LDL-C levels couldn’t tell us: atherosclerosis is already present.
More testing isn’t often needed. A more practical next step is to determine whether those findings warrant changes to lipid-lowering therapy, blood pressure management, nutrition, exercise, or other parts of his prevention plan.
At Biograph, we don’t use a single cholesterol number to determine whether your heart is healthy. Our cardiovascular evaluation brings together a standard lipid panel with advanced biomarkers such as:
ApoB
Lp(a)
hs-CRP
Your blood pressure, metabolic health, medical and family history, fitness, and other clinical information is also taken into consideration when assessing your cardiovascular health. When appropriate, coronary calcium scoring or CT coronary angiography can help directly assess your arteries.
More testing doesn’t always translate to better for you. The real value comes from using those findings to guide actionable care. Elevated ApoB may warrant lowering atherogenic particle burden, while high Lp(a) may affect how aggressively we manage modifiable cardiovascular risk factors. If imaging reveals plaque, its characteristics and extent can further inform a comprehensive prevention plan.
Commonly asked questions about normal cholesterol and heart disease risk
Can you have a heart attack if your cholesterol is normal?
Yes. Cholesterol is an important cardiovascular risk factor, but it isn’t the only one. Blood pressure, smoking, diabetes and metabolic health, genetics, inflammation, family history, atherogenic particle burden, and existing arterial plaque can all contribute to risk.
What is the difference between LDL cholesterol and ApoB?
LDL-C measures the amount of cholesterol carried inside LDL particles. ApoB provides a more direct measure of the number of circulating atherogenic particles, including LDL, VLDL, and Lp(a). When ApoB and LDL-C are discordant, ApoB can provide additional information about cardiovascular risk.
What is a healthy ApoB level for longevity?
There isn’t one ApoB target that’s appropriate for everyone. Treatment goals should reflect your overall cardiovascular risk and whether you already have atherosclerotic cardiovascular disease or other high-risk conditions. Rather than interpreting ApoB against a generic “normal” laboratory range, your physician can determine an appropriate target based on your complete clinical picture.
Why doesn't standard insurance cover ApoB or Lp(a) testing?
Coverage varies by insurer, plan, indication, and location, so there isn't one universal answer. ApoB and Lp(a) have historically been ordered less routinely than standard lipid panels, although clinical guidance continues to evolve. The 2026 ACC/AHA guidelines now recommend measuring Lp(a) at least once in all adults and recognize ApoB testing as useful under specific circumstances.
If my calcium score is zero, does that mean I have zero heart disease?
Not necessarily. A CAC score of zero means no calcified coronary plaque was detected on that examination. It doesn’t rule out non-calcified plaque, which CT coronary angiography can detect. Whether further evaluation is appropriate depends on your age, symptoms, family history, risk factors, and other clinical information.
Dr. Michael Doney is Biograph’s Executive Medical Director, with over 20 years of experience leading clinical care and advancing a more proactive, data-driven approach to medicine.
Clinical references
Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: An analysis of 136,905 hospitalizations in Get With The Guidelines. American Heart Journal. 2009;157(1):111-117.e2. doi:10.1016/j.ahj.2008.08.010
Fernández-Friera L, Fuster V, López-Melgar B, et al. Normal LDL-Cholesterol Levels Are Associated With Subclinical Atherosclerosis in the Absence of Risk Factors. Journal of the American College of Cardiology. 2017;70(24):2979-2991. doi:10.1016/j.jacc.2017.10.024
Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation. 2019;140(11):e596-e646. doi:10.1161/cir.0000000000000678
Genedy N, Zouwail S. ApoB/LDL-C discordance as a predictor of atherosclerotic cardiovascular disease in genetically confirmed heterozygous familial hypercholesterolemia: A hypothesis-generating cohort study. Journal of Clinical Lipidology. 2026;20(3):490-503. doi:10.1016/j.jacl.2025.11.008
Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Disease. JAMA Cardiology. Published online October 23, 2019. doi:10.1001/jamacardio.2019.3780
Stan D, Fu J, Ngov M, Doney M. Prevalence and clinical correlates of coronary perivascular inflammation in an asymptomatic adult primary prevention population: an assessment of the CT-derived fat attenuation index score (FAI-Score). medRxiv. Published online October 20, 2026. doi:10.64898/2026.10.19.26364786
